Role of contrast enhanced ultrasound in characterization of focal liver lesions  by Thakur, Shruti et al.
The Egyptian Journal of Radiology and Nuclear Medicine (2014) 45, 7–17Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLERole of contrast enhanced ultrasound
in characterization of focal liver lesions* Corresponding author. Tel.: +91 9418500500.
E-mail addresses: tshruti878@yahoo.in (S. Thakur), bhavuvasu@r-
ediffmail.com, dsdhiman@rediffmail.com (D.S. Dhiman),
drrgsood@gmail.com (R.G. Sood), drarunchauhan@yahoo.com (A.
Chauhan), drcharuthakur99@gmail.com (C.S. Thakur).
1 Tel.: +91 9418100180.
2 Tel.: +91 9418076465.
3 Tel.: +91 9418206920.
4 Tel.: +91 9418033264.
5 Tel.: +91 9418481310.
Peer review under responsibility of Egyptian Society of Radiology and
Nuclear Medicine.
Production and hosting by Elsevier
0378-603X  2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear Medicine.
http://dx.doi.org/10.1016/j.ejrnm.2013.11.001Open access under CC BY-NC-ND license.Shruti Thakur *, Anupam Jhobta 1, D.S. Dhiman 2, R.G. Sood 3, Arun Chauhan 4,
Charu S. Thakur 5Department of Diagnostic Radiology and General Surgery, Indira Gandhi Medical College and Hospital, Shimla,
Himachal Pradesh, IndiaReceived 29 April 2013; accepted 3 November 2013
Available online 5 December 2013KEYWORDS
Conventional baseline
sonography;
Contrast enhanced
sonography;
Focal liver lesions;
Microbubble contrast agentAbstract Aim: The purpose of the study was to describe the enhancement patterns of focal liver
lesions (FLLs) on contrast enhanced sonography (CEUS), assessing the potential of this technique
for characterizing the lesions and to compare its diagnostic accuracy with conventional baseline
sonography including color Doppler.
Materials and methods: Between August 2009 and July 2010, 50 patients with FLLs underwent
gray scale sonography, color Doppler and CEUS. The enhancement patterns of these FLL’s were
analyzed throughout the arterial phase, the portal venous phase and the extended portal venous
phase (the late parenchymal phase). The ﬁnal diagnosis was established on the basis of histopath-
ologic examination or CT/MRI imaging.
Results: Out of these 50 FLLs, 33 were malignant (4 hepatocellular carcinoma and 29 metastasis)
and 17 were benign (5 hemangioma, 5 abscess, 2 cyst and 1 each of FNH, focal fat sparing area,
focal fatty inﬁltration, adenoma and benign/granulomatous lesion). The enhancement patterns after
injecting microbubble contrast agent allowed characterization of FLLs. The malignant lesions
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8 S. Thakur et al.showed intratumoral and/or peritumoral vascularity during the arterial phase and perfusion defect
during the late parenchymal phase. Contrast enhanced sonography improved sensitivity in detecting
malignancy (CEUS vs. baseline sonography, 100% vs. 81.8%).
Conclusion: CEUS improves detection and characterization of FLLs. It should be used as problem
solving tool in cases where conventional gray scale and color Doppler sonography are non-diagnos-
tic.
 2014 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
Liver is a home for variety of focal lesions. Once identiﬁed, it
becomes necessary to characterize these lesions as it has
important therapeutic consequences. Conventional gray scale
sonography lacks speciﬁcity and sensitivity; however it is the
most common imaging modality for screening purposes. When
augmented with color Doppler, it gives better results in charac-
terization of lesions. It was further strengthened by introduc-
tion of microbubble contrast agents for sonography in the
mid 1990s (1). Contrast enhanced ultrasound (CEUS) uses
contrast agents that constitute of microbubbles of gas, stabi-
lized with coating of a biocompatible surfactant or polymer
like phospholipid or protein (2). These microbubble contrast
agents are purely intravascular, safe, well-tolerated and are
easy to administer, hence do not harm the patient (3). These
contrast agents are not excreted by the kidneys, so, deranged
renal function is not a contraindication for contrast enhanced
sonography, which is an advantage over CT and MRI (4).
CEUS allows accurate characterization of very small lesions
where even CT and MRI may fail (5). CEUS has evolved as
a problem solving tool for the characterization of focal liver
lesions (FLLs). It depicts rapid dynamic changes, largelyracterization of FLLs.
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The objective of this study was to describe the characteristic
enhancement patterns of various FLLs on CEUS, assessing the
potential of this technique for characterizing these lesions and
to compare its diagnostic accuracy with conventional baseline
sonography including color Doppler.2. Materials and methods
Between August 2009 and July 2010, a prospective study was
conducted and included ﬁfty patients (29 males and 21
females) with a mean age of 52 years (age range from 22 to
79 years). The inclusion criteria were (1) patients of cirrhosis
being evaluated for hepatocellular carcinoma (HCC), (2)
suspected liver metastasis and (3) incidental detection of focal
liver lesions (FLLs) on sonography. The exclusion criteria were
(1) history of allergy to drugs or other contrast agents, (2)
critically ill or medically unstable patients, (3) portal vein
thrombosis because of possibility of impaired hemodynamics,
and (4) pregnant patients. Written informed consent was taken
from all patients.ia CEUS criteria
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Table 2 Comparison of conventional baseline sonography and CEUS in characterization of FLLs.
Characterization of FLLs Baseline sonography CEUS FNAC/CT/MRI
True positive False positive Total True positive False positive Total Total
HCC 2 2 4 4 2 6 4
Metastases 22 1 23 27 0 27 29
Hemangioma 5 2 7 4 0 4 5
Abscess 3 0 3 5 0 5 5
Cyst 1 0 1 2 0 2 2
FNH 1 0 1 1 0 1 1
Focal fat sparing (FFS) 1 0 1 1 0 1
Focal fatty inﬁltration (FFI) 1 0 1 1 1 2 1
Adenoma – 1 0 1 1
Benign/granulomatous lesion – 1 0 1 1
Indeterminate 9 – –
Total 50 50 50
Role of contrast enhanced ultrasound in characterization of focal liver lesions 9Baseline sonography which included gray scale and color
Doppler ultrasound was performed in all patients. Blood ﬂow
was classiﬁed subjectively as absent or no vascularity, periph-
eral, peripheral and intralesional and intralesional only
depending on the blood vessels seen within or around the
tumor.
Contrast enhanced sonography was performed on a Xario
XG (Toshiba) machine using SonoVue (Braco, Milan, Italy)
as the contrast agent. Contrast was reconstituted by adding
5 ml of saline to a vial containing sterile lyophilized powder
to form a microbubble suspension. 2.4 ml of contrast agent
was injected intravenously through 18/20G cannula in a bolus
fashion, followed by 5 ml ﬂush of normal saline. Each patient
received only one injection.
The ultrasound machine was enabled with a contrast spe-
ciﬁc mode, using technical settings like frame rate and focal
zone optimized to obtain images of best quality. The mechan-
ical index (MI) was kept low (<0.2). Zero time was recorded
at the completion of the saline ﬂush. Real time imaging of
microbubble contrast agent was done throughout the arterial
phase (15–25 s), the portal venous phase (25–100 s) and the
extended portal venous phase (100–300 s) in both the liver ves-
sels and the parenchyma. If multiple lesions were present, the
largest lesion was observed.
The contrast enhancement pattern was classiﬁed (6) as
Absent/No vascularity: no difference in enhancement between
the lesion before and after contrast injection, Dotted: tiny sep-
arate spots of enhancement distributed throughout the lesion,
Rim-like/Peripheral: a continuous rim of peripheral contrast
enhancement, Nodular/Peripheral nodular: discontinuous or
continuous peripheral enhancement and a nodular appear-
ance, Central/intratumoral: enhancement of the central
portion of the lesion, Diffuse/peripheral and intratumoral:
homogeneous or heterogeneous enhancement of the entire
lesion, Perfusion defect: washout of contrast from the lesion
with appearance of hypoechoic area in the background ofTable 3 Enhancement pattern of HCC on CEUS.
Arterial phase Portal venous phase
Intratumoral/central vessels Perfusion defect
Intratumoral/central vessels Homogeneous or heterogeneous/diﬀunormally enhancing liver parenchyma, Residual enhancement:
persistence of contrast enhancement in the lesion on late
parenchymal phase.
3. Image analysis
Both gray scale/Doppler and contrast enhanced images were
retrospectively analyzed by a radiologist who was blinded to
each patient’s identiﬁcation, clinical history, histopathologic
and other imaging results. The lesions were categorized as be-
nign and malignant and further subclassiﬁed according to the
histopathologic criteria wherever possible. The comparison of
the results was made on the observation of the blinded obser-
ver. The criteria for characterizing the lesions as benign or
malignant are given in Table 1.
Histopathologic examination (HPE) was used as the gold
standard, and wherever HPE was not possible, ﬁnal diagnosis
was obtained on the basis of CT/MRI ﬁndings.
4. Statistical analysis
The sensitivity, speciﬁcity, positive predictive value and nega-
tive predictive value of conventional sonography as well as
contrast enhanced ultrasound were calculated and the values
expressed in percentages.
5. Results
Out of a total of ﬁfty FLLs, 33 proved to be malignant and 17
benign on HPE or CT/MRI as shown in Table 2. Of the 33
malignant lesions 4 were HCC and 29 were metastasis.
On conventional (baseline) sonography 27 lesions were
diagnosed as malignant (n= 27%, 54%), 14 as benign
(n= 14%, 28%) and rest 9 were indeterminate (n= 9%,
18%) in which no single diagnosis was possible.Late parenchymal phase Frequency
Perfusion defect 5
se enhancement Perfusion defect 1
Table 4 Enhancement patterns of metastases on contrast enhancement.
Arterial phase Portal venous phase Late parenchymal phase Frequency
Peritumoral vessels Perfusion defect Perfusion defect 10
Perfusion defect Perfusion defect Perfusion defect 9
Intratumoral vessels Homogeneous or heterogeneous enhancement Perfusion defect 4
Peritumoral vessels Homogeneous or heterogeneous enhancement Perfusion defect 2
Intratumoral vessels Peripheral nodular enhancement Perfusion defect 1
Intratumoral vessels Ring enhancement Perfusion defect 1
Total 27
Fig. 1 HCC in a 60-year-old man. (A) Color Doppler shows peritumoral vascularity. (B) CEUS-arterial phase shows intratumoral
enhancement. (C) Portal venous phase shows diffuse enhancement and (D) late parenchymal phase shows wash out of contrast with
perfusion defect (E) CECT-shows heterogeneous enhancement of the FLL.
10 S. Thakur et al.
Role of contrast enhanced ultrasound in characterization of focal liver lesions 11Oncontrast enhanced sonography, 33 lesionswere diagnosed
asmalignant and17 lesions as benign. Six lesionswere diagnosed
as HCC of which 4 were true positive and 2 were false positive.
CEUS enhancement pattern of HCC is given in Table 3.Fig. 2 Metastatic malignant melanoma in a 70-year-old man. (A) Gr
lesions. (B) Color Doppler shows absent vascularity. (C) CEUS-arter
(E) CEUS-late parenchymal phase shows perfusion defect. The lesionThe 2 false positive lesions proved to bemetastases onFNAC.
So, the sensitivity of CEUS in diagnosing HCC was 100%.
However, the speciﬁcity, positive predictive value and negative
predictive value were 95.6%, 66.7% and 100%, respectively.ay scale sonography shows ill deﬁned heterogeneously hyperechoic
ial phase shows no enhancement. (D) CEUS-portal venous phase
s are more conspicuous on CEUS.
Fig. 3 Hemangioma in a 39-year-old man. (A) Gray scale sonography shows heterogeneously hyperechoic lesion. (B) Color Doppler
shows peripheral vascularity. (C) CEUS-arterial phase shows rim enhancement. (D) CEUS-portal venous phase shows peripheral nodular
enhancement. (E) CEUS-late parenchymal phase shows residual enhancement with isoechogenecity to normal liver parenchyma. (F) and
(G) CECT shows peripheral nodular enhancement with central ﬁll in.
12 S. Thakur et al.
Role of contrast enhanced ultrasound in characterization of focal liver lesions 13Out of 29 metastatic lesions, 27 were correctly diagnosed as
hepatic metastasis on CEUS. The 2 false negative cases were
diagnosed as HCC on CEUS. All the metastatic lesions
showed perfusion defect on late parenchymal phase. CEUS
enhancement pattern of metastasis is shown in Table 4.
So, the sensitivity, speciﬁcity, positive predictive value and
negative predictive value of CEUS in diagnosing metastases
were 93.1%, 100%, 100% and 91.3%, respectively.
Of the 5 hemangiomas, all 4 diagnosed on CEUS showed
perilesional enhancement on arterial phase, perinodular
enhancement on portal venous phase and were homogeneous
to liver on late parenchymal phase. One hemangioma which
was missed showed no vascularity on any of the phases and
was diagnosed as focal fatty inﬁltration on CEUS. Therefore,
the sensitivity, speciﬁcity, positive predictive value andFig. 4 Hemangioma in a 54-year-old woman. (A) Gray scale sonogr
image shows no vascularity. (C) CEUS-arterial phase (D) portal venou
misdiagnosed as focal fatty sparing. (F) CECT show peripheral nodulnegative predictive value of CEUS in diagnosing hemangioma
were 80%, 100%, 100% and 97.8%, respectively.
Hepatic abscesses were diagnosed in 5 cases on CEUS
which were all positive on CT/serology. They showed perile-
sional vascularity on arterial phase, ring enhancement on
portal venous phase and retained their enhancement pattern
on late parenchymal phase. All the abscesses in our study
showed dense rim of opaciﬁcation with a persistent hypoechoic
center. Also, both the external and internal margins became
sharper after contrast administration (Fig. 5).
Two lesions showed no vascularity in any phase and were
diagnosed as cysts. One lesion which showed intratumoral vas-
cularity with central feeding vessel on arterial phase, diffuse
enhancement on portal venous phase and residual enhance-
ment on late parenchymal phase, was diagnosed as FNHaphy shows homogeneous hyperechoic lesion. (B) Color Doppler
s phase (E) late parenchymal phase show no enhancement, hence,
ar enhancement.
14 S. Thakur et al.(Fig. 6). The lesion diagnosed as adenoma (n= 1) showed
peritumoral enhancement on arterial phase, diffuse enhance-
ment on portal venous phase and residual enhancement on late
parenchymal phase (Fig. 7). Focal fat sparing and focal fatty
inﬁltration had enhancement pattern similar to that of normal
liver parenchyma.
6. Discussion
Hepatic lesions may be detected on surveillance scans in symp-
tomatic patients or may be incidentally seen on sonography.
On conventional gray scale sonography, there is considerable
overlap in the appearances of focal liver lesions. Today, how-
ever, contrast-enhanced ultrasound (CEUS) is excellent in
characterization and detection of most focal liver lesions.
SH U 508 (Levovist) is a ﬁrst generation, air ﬁlled micro-
bubble contrast agent. The studies using Levovist showed that
it improved the detection and characterization of FLLs (7).
However, it required imaging at high mechanical index to
obtain a strong harmonic response from destruction of Levo-
vist microbubbles to visualize the contrast enhancement. It
produced nonlinear emission signals from the destroyed
bubbles. Therefore, its capability for proper real time imaging
was limited as the investigator had to reduce the scanningFig. 5 Hepatic abscess in a 22-year-old man. (A) Gray scale shows
Color Doppler shows no vascularity. (C) CEUS-arterial phase shows
shows persisting rim enhancement.frame rate signiﬁcantly to permit the reaccumulation of
microbubbles into the area of interest. So it was substantially
incompatible with real-time scanning, a fundamental aspect
of modern ultrasound imaging.
This incompatibility was overcome by the development of
the second generation microbubble contrast agents such as
SonoVue (Bracco), Deﬁnity (Bristol–Myers Squibb) and Sona-
zoid (Amersham Health). SonoVue is a sulfur hexaﬂuoride
ﬁlled microbubble contrast agent stabilized by phospholipids.
The nonlinear vibration properties of these microbubbles
enable the use of a low mechanical index (MI < 0.2), which
prevents microbubble destruction thereby preserving the
microbubbles throughout their half-life in microvessels and
allowing real-time examination of liver vasculature (7). It
allows continuous assessment of the vessel as contrast agent
traverses the imaging ﬁeld, yielding the distribution and
morphology of the vessels, providing information that is only
occasionally seen on CT and MRI. With careful analysis of
characteristic enhancement patterns, CEUS can provide accu-
rate diagnosis of hepatic malignancy. Apart from its diagnostic
potential, it may be a useful alternative to CT and MRI for the
assessment of treated liver lesions by percutaneous ablation,
intra-arterial transcatheter chemoembolization or systemic
chemotheraphy (8).a well deﬁned heterogeneous hypoechoic lesion in right lobe. (B)
intense peritumoral enhancement. (D) CEUS-portal venous phase
Role of contrast enhanced ultrasound in characterization of focal liver lesions 15In our study, out of 33 malignant lesions, 27 were correctly
diagnosed on baseline sonography. In these, 4 were HCC, out
of which 2 were true positive and 2 were false positive. 23 were
metastases, out of which 22 were true positive and one was
false positive. Therefore, the sensitivity, speciﬁcity, positive
predictive value and negative predictive value of this modality
in diagnosing malignant lesions were 81.8%, 100%, 100% and
73.9%, respectively. Chami et al. (9) conducted a study in
which they found the sensitivity and speciﬁcity of gray scale
sonography in detecting malignant lesions to be 58.8% and
50.7%. The increased sensitivity and speciﬁcity in our study
were because of augmentation of gray scale ultrasound with
color Doppler.
In our study 6 lesions were diagnosed as HCC on CEUS,
out of which 2 were false positive. Out of the 4 correctly diag-
nosed HCC, 3 showed intratumoral vascularity on arterial
phase with perfusion defect on portal venous and late
parenchymal phases (3/4 = 75%). One HCC although hadFig. 6 FNH in a 22 year female. (A) On gray scale sonogram a hy
atypical spoke wheel pattern of enhancement and on porto venous phintratumoral vascularity on arterial phase, showed diffuse
enhancement on portal venous phase and ﬁnally perfusion
defect on late parenchymal phase (1/4 = 25%, Fig. 1). This
feature was also seen in a study conducted by Jang, et al.
(10) who observed broad variations in enhancement features
of HCC depending upon their histologic grade. 9% of all the
hypervascular HCC including 50% of well differentiated
HCC in their study did not show washout. In moderately dif-
ferentiated HCC which accounted for majority of their cases,
classic enhancement features of arterial phase hypervascularity
(96%) and portal venous phase washout (97%) were seen.
Similar ﬁndings were reported by Liu et al. (11) who found
that well differentiated HCCs showed contrast wash out more
slowly than poorly differentiated ones. In their study, the ech-
ogenicity of lesions in late phase correlated with tumor cellular
differentiation, hyperechoic lesions were likely to be well
differentiated whereas hypoechoic lesions were more likely to
be poorly differentiated.perechoic lesion is seen in liver. (B) CEUS-arterial phase shows
ase (C) it is isoechoic to liver.
16 S. Thakur et al.In the 33 metastatic lesions studied by Kim et al. (12) the
arterial contrast enhancement pattern was as follows: rim like
in 16 (48%), diffuse in 9 (27%) i.e. homogeneous in seven
(21%), and stippled in two (6%)); in the remaining eight
metastases (24%), no enhancement was seen. Similarly in
our study, out of 29 lesions, 12 showed peritumoral/rim-like
vessels (12/29 = 41.4%), 8 showed intratumoral vessels (8/
29 = 27.6%) and no tumor vessel was found in 9 lesions (9/
29 = 31.0%) on arterial phase. All the metastatic lesions
showed perfusion defect on late parenchymal phase.
In one lesion seen on baseline sonography no diagnosis was
possible; however, it was diagnosed as metastasis on CEUS
with increased conspicuity of the lesions. Another case
although diagnosed as metastasis on both baseline and con-
trast enhanced sonographies, showed that CEUS increased
the visibility of the lesions, with more clearly deﬁned margins,
size and also showed more number of lesions in postcontrast
scanning (Fig. 2). This certainly has bearing on treatment
options and results if percutaneous ablation, intra-arterial
transcatheter chemoembolization, systemic chemotheraphy or
partial hepatectomy is contemplated.
Out of total of 5 hemangiomas 4 showed typical enhance-
ment pattern of hemangiomas (Fig. 3). The hemangioma
which was not diagnosed on CEUS showed no vascularity
on any of the three phases of enhancement (Fig. 4). A possible
explanation for such an enhancement pattern was given byFig. 7 Adenoma in a young female. (A) Gray scale sonogram shows
diffuse heterogenous enhancement, which on porto venous phase (C)Michele Bertolotto et al. (8) who proposed that it might be
due to extensive thrombosis or ﬁbrotic changes in hemangioma
causing absent or minimal contrast enhancement not adequate
for its diagnosis. Similarly, presence of central scar in giant
hemangiomas causes their partial ﬁll in with no enhancement
seen in the central scar tissue (13). On gray scale, this lesion
was oval, homogeneously hyperechoic with well deﬁned
margins and showed no vascularity on color Doppler, so, diag-
nosed as hemangioma. Therefore, in this case conventional
baseline sonography proved to be superior to CEUS.
One lesion in our study was diagnosed as benign lesion and
its further characterization was not possible on CEUS. It
showed intratumoral enhancement on arterial phase, diffuse
enhancement on portal venous phase and residual
enhancement even on late parenchymal phase. Based on these
enhancement features, as there was no washout of contrast, the
diagnosis of benign lesion was given. On FNAC, it was diag-
nosed as granulomatous lesion, thereby, conﬁrming its
benignity.
7. Conclusion
Contrast enhanced sonography due to its non–invasive, non–
irradiating and real time imaging capability has signiﬁcantly
improved the diagnostic efﬁcacy in focal liver lesions. The
present study shows that CEUS can diagnose malignantan oval hypoechoic lesion in liver. (B) CEUS-arterial phase shows
is isoechoic to liver parenchyma.
Role of contrast enhanced ultrasound in characterization of focal liver lesions 17lesions with a sensitivity and speciﬁcity reaching 100%.
However, the cost of generalized use of contrast enhanced
sonography to exclude liver metastases in all patients with
extrahepatic cancer is excessive. Therefore it is necessary to
identify subpopulations of patients who may beneﬁt from this
approach and in such patients; a real capillary spread is still
required. Hence, it is concluded that CEUS should be used
as a problem solving tool in cases where conventional gray
scale and color Doppler sonography are non-diagnostic.
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